Savara will hold an investor call to review the key findings from the important Phase 3 IMPALA-2 trial of Molgramostim Nebulizer Solution in patients with aPAP.

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow…

Read More: https://www.businesswire.com/news/home/20240625514690/en/